Cargando…

Dyslipidaemia of Obesity, Metabolic Syndrome and Type 2 Diabetes Mellitus: the Case for Residual Risk Reduction After Statin Treatment

Dyslipidaemia is frequently present in obesity, metabolic syndrome (MetS) and type 2 diabetes mellitus (T2DM). The predominant features of dyslipidaemia in these disorders include increased flux of free fatty acids (FFA), raised triglyceride (TG) and low high density lipoprotein cholesterol (HDL-C)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Athyros, Vasilios G, Tziomalos, Konstantinos, Karagiannis, Asterios, Mikhailidis, Dimitri P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Open 2011
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3109607/ https://www.ncbi.nlm.nih.gov/pubmed/21660248 http://dx.doi.org/10.2174/1874192401105010024

Ejemplares similares

Dyslipidemia Induced by Drugs Used for the Prevention and Treatment of Vascular Diseases
por: Tziomalos, Konstantinos, et al.
Publicado: (2011)

Preventing Cardio-renal Syndrome Rather than Treating It: Could Statins Play A Role?
por: Athyros, Vasilios G, et al.
Publicado: (2011)

Is there an additional benefit from coronary revascularization in diabetic patients with acute coronary syndromes or stable angina who are already on optimal medical treatment?
por: Athyros, Vasilios G., et al.
Publicado: (2011)

Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients(§)
por: Athyros, Vasilios G, et al.
Publicado: (2007)

Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study
por: Athyros, Vasilios G., et al.
Publicado: (2013)

Differential residual dyslipidemia/cardiovascular risk after statin treatment between Asian-Indians and western whites. Call for action
por: Athyros, Vasilios Gabriel, et al.
Publicado: (2016)

Is There a Role for Hypolipidaemic Drug Therapy in the Prevention or Treatment of Microvascular Complications of Diabetes?
por: Mitsiou, Eydoxia K, et al.
Publicado: (2012)

Off target effects of statins shape total mortality?
por: Athyros, Vasilios G., et al.
Publicado: (2016)

The clinical benefit of implementing guidelines in cardiovascular disease prevention in real world settings
por: Athyros, Vasilios G., et al.
Publicado: (2012)

Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study
por: Athyros, Vassilios G., et al.
Publicado: (2011)

IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis
por: Athyros, Vasilios G., et al.
Publicado: (2011)

Comparative Effect of Atorvastatin and Rosuvastatin on 25-hydroxy-Vitamin D Levels in Non-diabetic Patients with Dyslipidaemia: A Prospective Randomized Open-label Pilot Study
por: Anagnostis, Panagiotis, et al.
Publicado: (2014)

Patient with Hypertriglyceridemia, Type 2 Diabetes, and Chronic Kidney Disease Treated with Atorvastatin and Omega-3 Fatty Acid Ethyl Esters
por: Athyros, Vasilios G, et al.
Publicado: (2012)

Single-pill combinations: a therapeutic option or necessity for vascular risk treatment?
por: Katsiki, Niki, et al.
Publicado: (2013)

Fenofibrate: a novel formulation (Triglide™) in the treatment of lipid disorders: a review
por: Tziomalos, Konstantinos, et al.
Publicado: (2006)

Are we getting to lipid targets in real life?
por: Katsiki, Niki, et al.
Publicado: (2010)

Implementation of Guidelines for the Management of Arterial Hypertension. The Impulsion Study
por: Karagiannis, Asterios, et al.
Publicado: (2009)

Statin Therapy and the Assessment of Hepatoprotection in Patients with Dyslipidaemia
por: Beznă, Marinela, et al.
Publicado: (2023)

Prevalence of dyslipidaemia in statin-treated patients in South Africa: results of the DYSlipidaemia International Study (DYSIS)
por: Raal, Frederick J, et al.
Publicado: (2013)

Is There an Association Between Carotid-Femoral Pulse Wave Velocity and Coronary Heart Disease in Patients with Coronary Artery Disease: A Pilot Study
por: Katsiki, Niki, et al.
Publicado: (2016)

Diabetic dyslipidaemia
por: C. Thambiah, Subashini, et al.
Publicado: (2021)

Dyslipidaemia in hypertensive obese type 2 diabetic patients in Jamaica
por: Gordon, Lorenzo, et al.
Publicado: (2010)

Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?
por: Reklou, Andromachi, et al.
Publicado: (2018)

The Role of Statins in the Management of Patients Undergoing Coronary Artery Bypass Grafting
por: Siskos, Dimitrios, et al.
Publicado: (2018)

More Good News on Statins and COVID-19
por: Katsiki, Niki, et al.
Publicado: (2021)

Herpes Zoster and Diabetes Mellitus: A Review
por: Papagianni, Marianthi, et al.
Publicado: (2018)

Plethora of adverse drug reactions in geriatric population receiving statin therapy for dyslipidaemia
por: Padhye, Mugdha R., et al.
Publicado: (2022)

Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? A pro/con debate
por: Hobbs, FD Richard, et al.
Publicado: (2016)

Virgin Coconut Oil: A Dietary Intervention for Dyslipidaemia in Patients with Diabetes Mellitus
por: Setyawati, Andina, et al.
Publicado: (2023)

Kidney Function and Estimated Vascular Risk in Patients with Primary Dyslipidemia
por: Tziomalos, Konstantinos, et al.
Publicado: (2009)

Association of homocysteinaemia with hyperglycaemia, dyslipidaemia, hypertension and obesity
por: Moraba, Mpho, et al.
Publicado: (2013)

The Associations between Kidney Function and Sexual Dysfunction among Males and Females with Type 2 Diabetes Mellitus
por: Katsimardou, Alexandra, et al.
Publicado: (2023)

Randomised study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Primary results of the BERSON clinical trial
por: Lorenzatti, Alberto J., et al.
Publicado: (2019)

Pathophysiology of diabetic dyslipidaemia: where are we?
por: Vergès, Bruno
Publicado: (2015)

Role of sodium-glucose co-transporter-2 inhibitors in the management of heart failure in patients with diabetes mellitus
por: Alkagiet, Stelina, et al.
Publicado: (2020)

Obesity and Outcome of Assisted Reproduction in Patients With Polycystic Ovary Syndrome
por: Tziomalos, Konstantinos, et al.
Publicado: (2018)

Postprandial metabolic heterogeneity in men with primary dyslipidaemia
por: Pavlidis, Antonios N., et al.
Publicado: (2010)

Prevalence of Dyslipidaemia among Type 2 Diabetes Mellitus Patients in the Western Cape, South Africa
por: Omodanisi, Elizabeth I., et al.
Publicado: (2020)

New-Onset Diabetes Mellitus, Hypertension, Dyslipidaemia as Sequelae of COVID-19 Infection—Systematic Review
por: Wrona, Marysia, et al.
Publicado: (2022)

Pharmacological Management of Obesity in Patients with Polycystic Ovary Syndrome
por: Kourtidou, Christodoula, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1hsq16h0ukogsus6268gtsib81